Kala Bio missed the primary endpoint in the study for its treatment of Persistent Corneal Epithelial Defect, an eye defect, and said it would stop development of the drug, called KPI-012. The company ...
Credit: Thinkstock. KPI-012 is a topically dosed ophthalmic therapy designed using the Company's human mesenchymal stem cell secretome platform. The Food and Drug Administration (FDA) has granted Fast ...
-- On-track to initiate Phase 2b trial in 1Q 2023; Topline data expected in 1Q 2024 -- -- Received remaining $25 million investment under previously announced private placement financing -- ARLINGTON, ...
Please provide your email address to receive an email when new articles are posted on . All eyes that received a single-layer graft and a 24-hour pressure patch showed complete healing. A three-layer ...
ARLINGTON, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization ...
KALA BIO completes patient enrollment in CHASE trial, evaluating KPI-012 for treating persistent corneal epithelial defect, with results due Q3 2025. KALA BIO, Inc. announced the completion of patient ...
-- On-track to initiate Phase 2b trial in 4Q 2022, with topline data expected in 1Q 2024 -- -- Cash runway extended into 1Q 2025, pending receipt of second tranche from previously announced financing, ...
Researchers headed by a team at Mass Eye and Ear, Harvard Medical School, reported positive data from a Phase I clinical study evaluating a stem cell treatment known as cultivated autologous limbal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback